Introduction LianBio operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs. The company is actively developing a portfolio of clinically validated product candidates spanning various therapeutic areas, including cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications. LianBio was founded by Konstantin Poukalov on July 17, 2019, and is headquartered in Princeton, NJ. The company is dedicated to advancing innovative therapies to benefit patients with diverse medical needs. |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 7 |
Contrast agent | 1 |
Target |
Mechanism GluCls inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date24 Jul 2023 |
Target |
Mechanism Cardiac myosin inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date28 Apr 2022 |
Mechanism FGFR1 antagonists [+3] |
Active Org. |
Originator Org. QED Therapeutics, Inc.Startup |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date28 May 2021 |
Start Date07 Nov 2023 |
Sponsor / Collaborator |
Start Date19 Oct 2023 |
Sponsor / Collaborator |
Start Date27 Jul 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Mavacamten ( Cardiac myosin ) | Hypertrophic obstructive cardiomyopathy More | Approved |
Hafnium oxide nanoparticles | Locally Advanced Head and Neck Squamous Cell Carcinoma More | Phase 3 |
Lotilaner ( GluCls ) | Infestation by Demodex More | Phase 3 |
Mometasone Furoate ( GR ) | Chronic sinusitis More | Phase 2 |
Infigratinib Phosphate ( FGFR1 x FGFR2 x FGFR3 x FGFR4 ) | Advanced Malignant Solid Neoplasm More | Phase 2 |